BioCentury
ARTICLE | Company News

Effimune, OSE Pharma deal

March 14, 2016 7:00 AM UTC

Effimune and Orphan Synergy will merge to form newco OSE Immunotherapeutics. Effimune shareholders will own about 29% of the newco, and OSE will own the remainder. The deal is subject to shareholder a...